Healthy subjects, sedation, antihistamines, P-glycoproteintransporter, fMRI, attention. Gezonde proefpersonen, vermoeidheid, antihistamines, P-glycoproteinetransporter, fMRI, aandacht.
Conditions
Interventions
There are two testdays, with two fMRI scan sessions per testday.
The first (randomly assigned) testday consists of the following treatments:
Before scan 1: Placebo and 90 minutes later, before scan
Sponsors
Maastricht University
Eligibility
Inclusion criteria
Inclusion criteria: 1. Aged between 18 and 45 years; 2. Healthy volunteers; 3. BMI between 19 and 30; 4. Able to give a written informed consent; 5. Able to understand the protocol and to come to the visits; 6. Use of a contraceptive method (for women).
Exclusion criteria
Exclusion criteria: 1. Medical history of major medical, psychiatric illness or surgery which, in the judgement of the investigator, could jeopardize their health or is likely to modify their handling of the study drug; 2. Any non corrected visual defect or locomotor disorder which could interfere with the study; 3. Acute or chronic systemic disease or disorder; 4. History of hypersensitivity to H1 antihistamines, benzimidazoles or lactose; 5. Seasonal allergic rhinitis or urticaria treated by antihistamine; 6. History of alcohol or drug abuse.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The mean reaction time (ms) of the Attention Network Test (ANT). | — |
Secondary
| Measure | Time frame |
|---|---|
| Cognitive tests: 1. The attention network test; 2. The simple reaction time test; 3. MRI resting state; 4. The BOLD signal. | — |
Contacts
Public ContactSilke Conen
P.O. Box 616
Outcome results
None listed